Denali Therapeutics has staged a technical breakout — golden cross, rising on-balance volume, RSI 68, and bullish MACD — while analyst consensus implies approximately 53% upside, but both the price momentum and the upside case rest heavily on a single pipeline asset (tividenofusp alfa) in a company with no revenue, negative free cash flow, and a 2/9 financial health score.
Thesis pillars
- Single Asset Pipeline Concentration→Stable
- Analyst Consensus Upside Signal→Stable
- Pre Commercial Quality Constraints→Stable
- +2 more pillars — see the Why tab for full reasoning
Denali Therapeutics Inc. (DNLI) Stock Analysis
Healthcare · Biotechnology
Sell if holding. Engine safety override at $25.83: Quality below floor (1.2 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.0/10. Specifically: High short interest: 10%; Below-average business quality.
Denali Therapeutics is a clinical-stage biopharmaceutical company developing barrier-crossing biotherapeutics using its proprietary TransportVehicle platform to deliver large molecules to the brain. The lead program tividenofusp alfa for Hunter syndrome (MPS II) has a BLA under... Read more
Sell if holding. Engine safety override at $25.83: Quality below floor (1.2 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.0/10. Specifically: High short interest: 10%; Below-average business quality. Chart setup: No clear chart pattern; technical signals are mixed. Score 5.0/10, moderate confidence.
Passes 6/8 gates (positive momentum, clean insider activity, news events none recent, earnings proximity 38d clear, semi cycle peak clear, materials cycle peak clear). Fails on favorable risk/reward ratio. Suitability: speculative.
About Denali Therapeutics Inc.
About Denali Therapeutics Inc.
Denali Therapeutics' most advanced program, tividenofusp alfa for MPS II (Hunter syndrome), had a biologics license application under FDA priority review with a PDUFA target date of April 5, 2026 as the company's first potential commercial product. With $966.2 million in cash, cash equivalents and marketable securities at December 31, 2025, Denali estimated its capital sufficient to fund projected operations through at least twelve months. The company had an accumulated deficit of $2.05 billion at year-end 2025, with net losses of $512.5 million in 2025 versus $422.8 million in 2024.
Denali generates no product revenue and funds operations primarily through proceeds from equity offerings and collaboration payments from Biogen, Sanofi, and Takeda. Biogen is conducting the Phase 2b LUMA study of BIIB122/DNL151 for Parkinson's disease in 650 enrolled participants, with data expected in mid-2026 — a milestone that could trigger further payments. In April 2026, Takeda notified the company of its decision to terminate the 2018 Collaboration Agreement for DNL593 (PTV:PGRN) for frontotemporal dementia-granulin, citing strategic considerations unrelated to efficacy or safety; all rights in the program revert to Denali 60 days after notice. The company's ETV franchise targets a combined market opportunity of over $1 billion for tividenofusp alfa and DNL126 together and a collective market potential of over $5 billion for the broader ETV franchise — management estimates, not contracted revenue. In March 2025, Denali opened a clinical biomanufacturing facility in Salt Lake City, Utah, expanding internal manufacturing while maintaining a hybrid strategy with external contract manufacturers.
Show full overview
The April 5, 2026 PDUFA date is a near-term binary event: in October 2025, the FDA extended its review by three months after classifying updated clinical pharmacology data as a Major Amendment — the company stated this extension was not related to efficacy, safety, or biomarkers. Separately, Denali disclosed in December 2025 that it may not be eligible to receive a Rare Pediatric Disease Priority Review Voucher upon approval, removing a potential non-dilutive capital source. Even if approved, tividenofusp alfa targets MPS II, a disease affecting over 2,000 individuals in commercially accessible geographies worldwide, limiting near-term revenue scale.
See also: Healthcare · Biotechnology
From Denali Therapeutics Inc.'s most recent 10-K filing, extracted June 9, 2026.
Recent developments
updated 2026-07-06Recent Developments — Denali Therapeutics Inc.
Latest news
- NEWS Denali Therapeutics Signs Deal To Sell Its Rare Pediatric Disease Priority Review Voucher For $195M — benzinga Jun 18, 2026 positive
- NEWS Morgan Stanley Maintains Overweight on Denali Therapeutics, Lowers Price Target to $35 — benzinga May 26, 2026 neutral
- NEWS Trading Halt: Halt status updated at 6:25:00 PM ET: Quotation Resumption: News and Resumption Times — benzinga May 21, 2026 neutral
- NEWS Biogen And Denali Discontinue BIIB122 Development In Idiopathic Parkinson's Disease After Phase 2b LUMA Trial Misses Pri — benzinga May 21, 2026 negative
- NEWS Trading Halt: Halted at 5:55:00 p.m. ET - Trading Halt: Halt News Pending — benzinga May 21, 2026 negative
Generated 2026-07-06T06:30:27Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHpipelinetividenofusp alfa10-K Item 1: 'The ETV franchise is intended to serve as the commercial and financial foundation of our business, with the anticipated launch of tividenofusp alfa'
Material Events(8-K, last 90d)
- 2026-04-03Item 1.02MEDIUMTakeda Pharmaceutical notified Denali on April 3, 2026 of its decision to terminate the 2018 Collaboration Agreement for DNL593 (PTV:PGRN). Termination effective 60 days after notice; all DNL593 rights revert to Denali. Decision driven by strategic considerations, not efficacy or safety.SEC filing →
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
2 floor-breakers
Quality below the gate floor. Component breakdown shows what dragged the score down.static
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $25.83: Quality below floor (1.2 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.0/10. Specifically: High short interest: 10%; Below-average business quality. Chart setup: No clear chart pattern; technical signals are mixed. Prior stop was $24.02. Score 5.0/10, moderate confidence.
Take-profit target: $30.54 (+18.2% upside). Prior stop was $24.02. Stop-loss: $24.02.
Concentration risk — Pipeline: tividenofusp alfa; Quality below floor (1.2 < 4.0).
Denali Therapeutics Inc. trades at a P/E of N/A (forward -10.4). TrendMatrix value score: 7.5/10. Verdict: Sell.
25 analysts cover DNLI with a consensus score of 4.4/5. Average price target: $34.
What does Denali Therapeutics Inc. do?Denali Therapeutics is a clinical-stage biopharmaceutical company developing barrier-crossing biotherapeutics using its...
Denali Therapeutics is a clinical-stage biopharmaceutical company developing barrier-crossing biotherapeutics using its proprietary TransportVehicle platform to deliver large molecules to the brain. The lead program tividenofusp alfa for Hunter syndrome (MPS II) has a BLA under FDA priority review with a PDUFA date of April 5, 2026; the company has not yet generated product revenue and had an accumulated deficit of $2.05 billion and $966.2 million in cash at December 31, 2025.